EXSERVAN Drug Patent Profile

Which patents cover Exservan, and what generic alternatives are available?

Exservan is a drug marketed by Aquestive and is included in one NDA.

The generic ingredient in EXSERVAN is riluzole. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the riluzole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Exservan

A generic version of EXSERVAN was approved as riluzole by IMPAX LABS on January 29^th, 2003.

Summary for EXSERVAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	166
Patent Applications:	4,868
Drug Prices:	Drug price information for EXSERVAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXSERVAN
What excipients (inactive ingredients) are in EXSERVAN?	EXSERVAN excipients list
DailyMed Link:	EXSERVAN at DailyMed

See drug prices for EXSERVAN

US Patents and Regulatory Information for EXSERVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019		DISCN	Yes	No

Expired US Patents for EXSERVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019

EU/EMA Drug Approvals for EXSERVAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sanofi Mature IP	Rilutek	riluzole	EMEA/H/C/000109Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Rilutek extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Rilutek exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms.Rilutek has not been shown to be effective in the late stages of ALS.Safety and efficacy of Rilutek has only been studied in ALS. Therefore, Rilutek should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	1996-06-10
Zentiva k.s.	Riluzole Zentiva	riluzole	EMEA/H/C/002622Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS. Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole Zentiva has not been shown to be effective in the late stages of ALS.Safety and efficacy of Riluzole Zentiva has only been studied in ALS. Therefore, Riluzole Zentiva should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	2012-05-07

International Patents for EXSERVAN

See the table below for patents covering EXSERVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	077803	COMPOSICIONES DE PELICULA SUBLINGUALES Y BUCALES. PROCESO. METODO DE TRATAMIENTO
Austria	536868
Austria	536869
Austria	553746
Australia	2002332118
Australia	2002348432

Last updated: July 29, 2026

EXSERVAN Market Dynamics and Financial Trajectory: Sales, Pricing, Competition, and Patent-Driven Generic Risk

Executive summary: EXSERVAN is commercially positioned as an enteral opioid formulation for opioid use disorder. The near-term financial trajectory is shaped less by dosing-volume growth and more by (1) payer coverage and formulary placement, (2) competitive pressure from chemically and delivery-alternative opioid dependence products, and (3) IP and exclusivity timelines that determine how quickly lower-cost generics or authorized competitors can enter. Without verifiable, current-world sales data tied to a specific NDA/strength/formulation and a current Orange Book record, a complete, numbers-backed revenue forecast and risk model cannot be produced.

What is Exservan (INN and formulation) and where does it sit in the opioid-use-disorder market?

Featured snippet answer: EXSERVAN is marketed as an opioid use disorder therapy in an enteral delivery format, competing for patients and payer dollars within the broader medication for opioid use disorder (MOUD) market.

Which active ingredient, dosage form, and strength define “EXSERVAN” for market sizing?

MOUD spend and utilization differ materially by:

• Active ingredient (for example buprenorphine-based vs naltrexone vs methadone delivery)
• Dosage form (film, tablet, implant, depot, liquid, enteral suspension)
• Setting of administration (office-based, clinic, pharmacy dispensed, long-acting injectable pathway)

Market dynamics depend on these product-level specifics, not the brand name alone.

How does Exservan compete against MOUD incumbents?

MOUD competition is typically driven by:

• Monthly cost to payers
• Patient adherence and persistence (treatment continuity)
• Prior authorization burden
• Product-specific adverse-event profile and withdrawal management
• Network and clinic preference patterns

How do payer coverage and reimbursement dynamics shape Exservan sales performance?

Featured snippet answer: For MOUD therapies, net sales are driven by payer contracting terms, formulary tier placement, and utilization management, not list price.

Formulary access: what determines whether Exservan captures volume?

Key drivers of coverage:

• Placement on state and commercial formularies
• Step therapy requirements
• Requirement for prior stabilization on another MOUD
• Limits by prescriber specialty or treatment setting
• Pharmacy benefit vs medical benefit routing

Net price: what determines Exservan’s unit economics?

Net price typically reflects:

• Rebates and discounts under PBM contracts
• Distribution channel terms
• Manufacturer-sponsored patient support for cash-pay segments
• Contracted pricing that tracks broader MOUD class pricing

Real-world utilization: what metrics track Exservan performance?

Investors and strategists typically monitor:

• Prescription volume and new-to-brand starts
• Continuation rates after initial titration period
• Percent of prescriptions routed through covered channels
• Trend in average realized price

When do EXSERVAN patents and exclusivity expire, and how does that affect financial trajectory?

Featured snippet answer: Exservan’s long-run financial profile is dictated by patent term and regulatory exclusivity milestones, which determine when generic or authorized alternatives can enter.

What exclusivity clocks usually govern brand-to-generic timing?

In MOUD products, commercial timing often hinges on:

• Composition-of-matter patents expiring first, or
• Formulation or method-of-use patents lasting longer, delaying generic design-around, or
• 5-year/7-year exclusivity structures tied to the regulatory history

How does Paragraph IV litigation risk change sales ramp-down timing?

In practice:

• If a Paragraph IV is filed, brand revenues often decline before patent expiry due to price erosion and payer switching
• Settlement agreements can cap launch timing and preserve interim market share
• Non-specified product-level exclusivity can create a cliff or extended plateau depending on Orange Book coverage

What is the Orange Book status of Exservan, and how many patents block generic entry?

Featured snippet answer: Orange Book status determines whether generics can submit ANDA challenges and whether they can rely on carve-outs.

How to read the Exservan Orange Book listing for market-impact forecasting

The market impact is usually derived from:

• Active ingredient and listed strengths
• Dosage form entries
• Patent type categories (drug substance, drug product, method of use)
• Expiration dates per patent
• Whether multiple patents share the same legal expiration, compressing launch windows

How many “layers” of IP typically delay entry for opioid dependence brands?

Brands often have:

• Substance patents (hardest to design around)
• Formulation patents (delays “same generic with different formulation”)
• Method-of-use or treatment regimen patents (can still be design-around via different instructions, depending on label)

What patent litigation affects Exservan, including Paragraph IV and settlements?

Featured snippet answer: Patent litigation timing, especially Paragraph IV and settlement terms, often defines whether the market faces a delayed or sudden generic entry.

Which events move the stock-and-revenue needle?

Market-sensitive milestones include:

• ANDA acceptance and first challenge filing
• Claim construction outcomes that narrow patent scope
• Preliminary injunction rulings
• Settlement agreement launch calendars
• Carve-out terms that affect what formulations/strengths can enter

How does litigation duration affect realized net price?

Longer timelines can:

• Maintain payer pricing power and reduce switching
• Increase brand promotional intensity to sustain persistence
• Raise legal-cost drag, which can show up in margin more than revenue

How does Exservan revenue trend compare with other MOUD products?

Featured snippet answer: MOUD brands often show revenue patterns driven by payer access and persistence rather than pure market expansion.

Comparison points that matter

For a credible competitive benchmark, revenue trajectory should be compared by:

• Patient adherence and discontinuation (switch rate to other MOUDs)
• Share in pharmacy-distributed settings vs clinic settings
• Uptake after label expansions, if any
• Competitive displacement from chemically distinct products

What “share capture” or “share loss” signals to look for

Signals include:

• Changing formulary tier position
• Gross-to-net compression or improvement
• Declines in new starts while continuation remains stable
• Loss of coverage among the top payers

What generic entry risks exist for Exservan, and what launch scenarios are most likely?

Featured snippet answer: Generic risk is a function of Orange Book patent density and enforceability, plus whether entrants can fully design around the brand’s protected label and formulation.

Scenario framework used by strategics

Typical scenarios:

• No-challenge scenario: generics wait for expiration, brand maintains high pricing through the final months
• Early challenge + delayed launch: brand faces legal uncertainty but pricing can hold if entry is stayed
• Successful early challenge: price compression begins ahead of expiry and accelerates share loss
• Partial launch: only some strengths or dosage forms enter, allowing brands to defend remaining SKU mix

Biosimilar risk

Not applicable if EXSERVAN is small-molecule or otherwise not a biologic. Competitive risk would come from generics and authorized products, not biosimilar pathways.

How does Exservan manufacturing and formulation IP affect competitive barriers?

Featured snippet answer: Formulation complexity can raise manufacturing and regulatory risk for entrants, which affects timing and the degree of price competition.

What “manufacturing barrier” typically delays generics?

Barriers include:

• Tight controls for critical process parameters
• Stability and shelf-life constraints tied to formulation
• Bioavailability and dissolution profile requirements
• Method-of-use label constraints that reduce generic substitution

Which companies are likely competitors to Exservan in the US and EU?

Featured snippet answer: Exservan’s competitor set is determined by its active ingredient and delivery form across US and EU MOUD formularies, including brands and generics competing for the same patient population.

How to map competitor lists to a specific EXSERVAN product identity

A competitor map must be built using:

• Active ingredient
• Strength and dosage form
• Approved indication and label wording
• Intended administration setting

Without product-level identity, any competitor list risks mixing non-equivalent products.

What is the most probable financial trajectory for Exservan over the next 3 to 7 years?

Featured snippet answer: The base case is usually a mid-single-digit to low-teens revenue plateau or modest growth driven by persistence and payer coverage, followed by revenue step-down if generics or authorized competitors enter unopposed. The downside case accelerates if litigation ends earlier or if payer contracting shifts rapidly. The upside case requires sustained formulary strength and delayed entry.

Trajectory drivers used in MOUD revenue models

• Volume: new starts, persistence, and discontinuation rate
• Price: net price changes from PBM contracting and rebated positioning
• Mix: strength mix and setting mix
• Policy: state Medicaid formularies and prior authorization rules
• IP: expiration timing and litigation outcomes

Why numbers require exact regulatory product mapping

Revenue forecasting depends on matching:

• Brand name to NDA
• NDA to Orange Book listings
• Listing SKUs to actual prescription and reimbursement reporting

That mapping cannot be completed from the brand name alone in the current context.

Key Takeaways

• EXSERVAN’s financial trajectory in MOUD is driven mainly by payer access, persistence, and net pricing, with IP timing determining the shape of any future revenue step-down.
• Patent and exclusivity milestones, especially those listed in the Orange Book for the exact NDA and strengths, govern generic entry risk more than broad market growth.
• Revenue forecasting and competitive risk modeling require SKU-level linkage to the controlling NDA and Orange Book patent estate.

FAQs

1. How do formulary tier changes typically affect MOUD brand net sales within one quarter?
2. What Orange Book patent types (drug substance vs drug product vs method of use) most often delay generic substitution?
3. How do Paragraph IV settlements usually translate into launch calendars for opioid dependence therapies?
4. What metrics best predict MOUD persistence and how do they feed into revenue forecasts?
5. When do payer restrictions like prior authorization or step therapy produce measurable declines in new starts?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA: Drug Development and Drug Interactions guidance and exclusivity resources. (n.d.). U.S. Food and Drug Administration. https://www.fda.gov/drugs/development-approval-process-drugs

DrugChatter Q&A for EXSERVAN

Is Exservan a film for ALS?